Velcade®: U.S. FDA Approval for the Treatment of Multiple Myeloma Progressing on Prior Therapy

• Published in: The oncologist (Dayton, Ohio) Vol. 8; no. 6; pp. 508 - 513
• Main Authors: Kane, Robert C., Bross, Peter F., Farrell, Ann T., Pazdur, Richard
• Format: Journal Article
• Language: English
• Published: Durham, NC, USA AlphaMed Press 01-12-2003
• Subjects: Accelerated approval; Antineoplastic Agents - pharmacology; Antineoplastic Agents - therapeutic use; Boronic Acids - pharmacology; Boronic Acids - therapeutic use; Bortezomib; Drug Approval; Humans; Multiple myeloma; Multiple Myeloma - drug therapy; Multiple Myeloma - pathology; Pyrazines - pharmacology; Pyrazines - therapeutic use; Randomized Controlled Trials as Topic; United States; United States Food and Drug Administration; Velcade; United States
• ISSN: 1083-7159; 1549-490X
• DOI: 10.1634/theoncologist.8-6-508

Learning Objectives
After completing this course, the reader will be able to:
Discuss the rationale and requirements for accelerated cancer drug approval by the U.S. Food and Drug Administration (FDA).
Identify the current indications for the use of a recently approved agent, bortezomib (Velcade®, PS‐341), in the treatment of multiple myeloma.
Describe the plans for the further clinical development of this agent as part of accelerated approval by the FDA.
Explain the mechanism of action of bortezomib and its role in cancer treatment.
Access and take the CME test online and receive one hour of AMA PRA category 1 credit at CME.TheOncologist.com
Bortezomib (formerly PS‐341), a promising new drug for the treatment of multiple myeloma, recently received accelerated approval from the U.S. Food and Drug Administration (FDA) for the therapy of patients with progressive myeloma after previous treatment. Two phase II studies of bortezomib used the same schedule of twice‐weekly i.v. dosing for the first 2 weeks of each 3‐week cycle. In a randomized study of 54 patients, two doses were compared (1.0 and 1.3 mg/m2) and objective responses occurred at both dose levels (23% versus 35%), including one complete response in each arm. In the other phase II study, 202 heavily pretreated patients (median of six prior therapies) all received the same schedule at 1.3 mg/m2. Of 188 evaluable patients, complete responses occurred in five (3%) and partial responses occurred in 47 (25%). The median duration of response was 365 days. The most clinically relevant adverse events were asthenic conditions, nausea, vomiting, diarrhea, thrombocytopenia, and a peripheral neuropathy that often was painful. This report highlights the FDA analysis supporting the accelerated approval.